Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy
- 10 March 2020
- journal article
- research article
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 121 (3) , 677-684
Abstract
Patients with intellectual disability (ID) are often excluded from clinical trials, and little is known about the best approach to treat their epilepsy. Brivaracetam (BRV) is a new antiepileptic drug (AED) for adjunctive treatment in patients with focal-onset seizures with or without secondary generalization. We analyzed the efficacy and tolerability of BRV in patients with ID and epilepsy who either had or had not previously received treatment with levetiracetam (LEV). Data on efficacy and tolerability were retrospectively collected. After the initial start of BRV in our tertiary epilepsy center, we analyzed medical records at 0, 3, 6 and 12 months of follow-up. 116 patients were included (mean age = 34.9 years, 44% female). All had complete data of 3-month follow-up, 76 of 6-month follow-up, and 39 patients of 1-year follow-up. Median starting dose of BRV was 50.0 mg/day and the mean number of concomitant AEDs was 2.6. Seizure reduction and no side effects were reported in more than half of all patients. The most reported side effects were somnolence, dizziness and aggression. Retention rates for BRV were 84.4%, 75.5% and 58.1% after 3, 6 and 12 months, respectively. Seizure reduction and side effects did not differ significantly between the groups with or without previous LEV treatment. We demonstrate that BRV is effective and well tolerated in patients with epilepsy and ID, even in those where previous LEV treatment failed.Keywords
This publication has 18 references indexed in Scilit:
- Brivaracetam add-on for refractory focal epilepsyNeurology, 2016
- A randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial‐onset seizuresEpilepsia, 2015
- Prevalence of epilepsy among people with intellectual disabilities: A systematic reviewSeizure: European Journal of Epilepsy, 2015
- Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double‐blind, placebo‐controlled trialEpilepsia, 2013
- Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double‐blind, randomized, placebo‐controlled trialEpilepsia, 2013
- Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double‐blind, randomized, placebo‐controlled, flexible‐dose trialEpilepsia, 2013
- Estimation of the burden of active and life‐time epilepsy: A meta‐analytic approachEpilepsia, 2010
- Epilepsy in adults with intellectual disabilities: Prevalence, associations and service implicationsSeizure: European Journal of Epilepsy, 2006
- Seizure freedom with different therapeutic regimens in intellectually disabled epileptic patientsSeizure: European Journal of Epilepsy, 2005
- Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effectsEpilepsy & Behavior, 2004